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Insulin glargine is a synthetic long-acting insulin product used for patients with diabetes mellitus. In this study, to obtain the
further desirable blood-glucose lowering proﬁle of insulin glargine, we investigated the eﬀects of β-cyclodextrin sulfate (Sul-β-
CyD) and sulfobutylether β-cyclodextrin (SBE7-β-CyD) on physicochemical properties of insulin glargine and pharmacokinetics/
pharmacodynamics of insulin glargine after subcutaneous injection to rats. Sul-β-CyD and SBE7-β-CyD increased solubility of
insulin glargine. SBE7-β-CyD suppressed the formation of oligomer and enhanced the dissolution rate of insulin glargine from its
precipitate, compared to thatofSul-β-CyD.Additionally,we revealed thataftersubcutaneous administrationofaninsulinglargine
solution, SBE7-β-CyD, but not Sul-β-CyD, increased bioavailability and sustained the blood-glucose lowering eﬀect, possibly due
to the inhibitory eﬀects of SBE7-β-CyD on the enzymatic degradation at the injection site. These results suggest that SBE7-β-CyD
could be a useful excipient for sustained release of insulin glargine.
1.Introduction
Diabetes is a rapidly growing health problem worldwide
and chronic disease wherein the pancreas does not produce
enough insulin (type 1 diabetes), or the body does not
respond correctly to insulin and relative insulin deﬁciency
(type 2 diabetes). It can be a life-threatening disease and can
also lead to serious complications such as cardiovascular
disease, kidney failure, blindness, and nerve damage [1–3].
According to the World Health Organization, the number
of people living with diabetes is estimated to increase from
172 million in 2000 to 366 million in 2030 [4]. The global
diabetesepidemichasdevastatingeﬀectsonnotonlypatients
and their families but also national economies.
Human insulin is a major backbone for the treatment
of diabetes. Although human insulin has contributed much
in clinical treatment of diabetes for a long time, there are
still some diﬃculties and challenges of hypoglycemia and
short half-life. In order to overcome these drawbacks, insulin
glargine (Lantus), an insulin analogue (C267H404N72O78S6,
MW = 6,063) was developed by replacing asparagine at the
position of 21 of the A chain with glycine, and two arginines
were added to the C-terminus of the B chain in human
insulin (Figure 1). It has a prolonged duration of action
after subcutaneous injection and, therefore, can provide a
basal insulin level for 24 hours by once daily injection [5].
This alteration results in low aqueous solubility at neutral
pH [6]. Insulin glargine is supplied in an acidic solution,
whichbecomesneutralizedattheinjectionsite,leadingtothe
formation of microprecipitates from which insulin glargine
is slowly released into the circulation [6].
Cyclodextrins (CyDs) are known to form inclusion
complexes with various guest molecules [7, 8]. However, the
low aqueous solubility of natural CyDs, especially β-CyD,2 Journal of Drug Delivery
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Figure 1: Amino acid sequence and location of intermolecular disulﬁde bonds of insulin glargine.
has restricted their range of applications. To improve their
solubility, alkylated, hydroxyl alkylated, sulfated, sulfobutyl
alkylated, and branched CyDs have been developed [9–12].
Of these hydrophilic CyDs, maltosyl-β-CyD (G2-β-CyD), 2-
hydroxypropyl-β-CyD (HP-β-CyD), β-CyD sulfate (Sul-β-
CyD) and sulfobutyl ether-β-CyD (SBE-β-CyD) have higher
solubility in water and relatively low hemolytic activity
and thus have potential as pharmaceutical excipients for
parenteral preparation [8, 9, 13]. In fact, natural β-CyD
has a toxic eﬀect on kidney, which is the main organ for
the removal of CyDs from the systemic circulation and for
concentrating CyDs in the proximal convoluted tubule after
glomerular ﬁltration [14]. Actually, amorphous mixtures of
highly water-soluble β-CyDs such as HP-β-CyD and SBE-β-
CyD have very low systemic toxicity, compared with β-CyD.
We previously reported the eﬀects of hydrophilic β-CyDs
on the aggregation of bovine insulin in aqueous solution
and its adsorption onto hydrophilic surfaces [15–17]. Of the
CyDs tested, G2-β-CyD potently inhibited insulin aggrega-
tioninaneutralsolutionanditsadsorptionontothesurfaces
of glass and polypropylene tubes. In addition, SBE-β-CyDs
showed diﬀerent eﬀects on insulin aggregation in phosphate
buﬀer (pH 6.8, I = 0.2), depending on the degree of
substitution (DS) of the sulfobutyl ether group, SBE4-β-CyD
(DS = 3.9) showed deceleration of insulin aggregation, and
SBE7-β-CyD (DS = 6.2) showed acceleration [17]. Further-
more, we reported that after subcutaneous administration
of insulin solution to rats, SBE4-β-CyD rapidly increased
plasma insulin level and maintained higher plasma insulin
levels for at least 8h, possibly due to the inhibitory eﬀects
of SBE4-β-CyD on the enzymatic degradation and/or the
adsorption of insulin onto the subcutaneous tissue at the
injection site [18]. More recently, we have demonstrated that
SBE4-β-CyD enhanced both bioavailability and prolonged
the blood-glucose lowering eﬀect of insulin glargine after
subcutaneous administration to rats, probably due to the
inhibitory eﬀects of interaction with SBE4-β-CyD on the
enzymatic degradation at the injection site [19]. However,
it is still unknown whether other anionic β-CyD derivatives
such as Sul-β-CyD and SBE7-β-CyD show the improved
bioavailability and sustained-glucose lowering eﬀects for
insulin glargine. Therefore, the objective in the present
study is to evaluate the potential use of anionic β-CyD
derivatives, such as Sul-β-CyD and SBE7-β-CyD, on not
only bioavailability of insulin glargine but also the sustained-
blood-glucoseloweringeﬀects.Inaddition,theeﬀectsofSul-
β-CyD and SBE7-β-CyD on physicochemical properties and
pharmacokinetics/pharmacodynamics of insulin glargine
were examined.
2.MaterialsandMethods
2.1. Materials. Insulin glargine was supplied by Sanoﬁ-
Aventis (Paris, France). SBE7-β-CyD was provided by CyDex
(Kansas, USA). Sul-β-CyD with an average degree of sub-
stitution of 10.7 was prepared by a nonregional selective
method as described previously [20]. Recombinant trypsin
(EC 3.4.21.4) of proteomics grade was purchased from
RocheDiagnostics(Tokyo,Japan).Phosphatebuﬀer(pH9.5,
I = 0.2) was prepared according to the US Pharmacopeia;
0.1mol/L phosphoric acid solution and 0.1mol/L sodium
hydroxide solution were mixed, followed by the addition
of sodium chloride. All other materials were of analytical
reagentgrade,anddeionizeddouble-distilledwaterwasused.
2.2. Spectroscopic Studies. Fluorescence and circular dichro-
ism (CD) spectra were measured at 25◦C using a HITACHI
ﬂuorescence spectrophotometer F-2500 (Tokyo, Japan) and
a JASCO J-720 polarimeter (Tokyo, Japan), respectively.
2.3. Solubility Studies. Excess amounts of insulin glargine
were shaken in phosphate buﬀer (pH 9.5, I = 0.2) in the
absence and presence of the selected anionic β-CyDs at 25◦C.
After equilibrium was attained, the solutions were ﬁltered
with Millex GV ﬁlter 0.22 μm, and the insulin glargine
dissolved was determined by high-performance liquid chro-
matography (HPLC) with Agilent 1100 series (Tokyo, Japan)
under the following conditions: Merck Superspher 100RP-
18 column (4 μm, 3mm × 250mm, Tokyo, Japan), a mobile
phase of phosphate buﬀer (pH 2.5) and acetonitrile and aJournal of Drug Delivery 3
gradient ﬂow, increasing the ratio of the acetonitrile (25–
40%) over 30min, a ﬂow rate of 0.55mL/min, a detection
of UV at 214nm.
2.4. Ultraﬁltration Studies. Ultraﬁltration studies were per-
formed using stirred ultraﬁltration cells model 8010 (Milli-
pore, Tokyo, Japan) applied with YM30 ultraﬁltration discs
(MWCO = 30,000) in phosphate buﬀer (pH 9.5, I = 0.2)
in the absence and presence of the selected anionic β-CyDs
at 25◦C under nitrogen current. Insulin glargine levels in
ﬁltrates were determined by HPLC as described above.
2.5. Particle Size Determination. Particle sizes of insulin
glargine (0.1mM) with or without the selected anionic
β-CyDs (10mM) in phosphate buﬀer (pH 9.5, I = 0.2)
were measured by Zetasizer Nano (Malvern Instruments,
Worcestershire, UK).
2.6. Dissolution Study of Insulin Glargine. Insulin glargine
(0.1mM) dissolved in phosphate buﬀer (pH 9.5, I = 0.2)
in the absence and presence of the selected anionic β-CyDs
(10mM) was precipitated by a pH shift to 7.4. After centrifu-
gation (2,500rpm, 10min), the supernatant was discarded,
and then phosphate buﬀer (pH 7.4, I = 0.2) was newly added
totheprecipitateat25◦C.Atappropriateintervals,analiquot
of the dissolution medium was withdrawn, centrifuged at
2,500rpm for 10min, and analyzed for the insulin glargine
by HPLC as described above.
2.7. Stability of Insulin Glargine against Tryptic Cleavage.
Insulin glargine (0.1mM) in phosphate buﬀer (pH 9.5, I =
0.2) was incubated with recombinant trypsin (0.02mg/mL)
in the absence and presence of the selected anionic β-CyDs
at 37◦C. At appropriate intervals, 5 μL of sample solution
was withdrawn and determined intact insulin glargine level
by HPLC. The rate constants (kc) and stability constants
(Kc) of 1:1 complexes of insulin glargine/β-CyDs under the
tryptic cleavage were determined by a quantitative analysis
according to the following equation, where k0 and [CyD]t
stand for the rate constants without CyD and the total
concentration of CyD, respectively [21]:

CyD

t
k0 −kobs
=
1
k0 −kc
·

CyD

t +
1
Kc · (k0 −kc)
. (1)
2.8. Pharmacokinetics and Pharmacodynamics of Insulin
Glargine. The solution (0.582mL/kg) containing insulin
glargine (2IU/kg) in phosphate buﬀer (pH 9.5, I = 0.2) in
the absence and presence of the selected anionic of β-CyDs
was subcutaneously injected in male Wistar rats (200–250g),
and, at appropriate intervals, blood samples were taken from
the jugular veins. Serum insulin glargine and glucose were
determined by Glyzyme Insulin-EIA Test Wako (Wako Pure
Chemicals,Osaka,Japan)andGlucose-CII-TestWako(Wako
Pure Chemicals Ind., Osaka, Japan), respectively. Serum
glucose levels after the administration of a solution of insulin
glargine with or without the selected anionic β-CyDs were
expressed as a percentage of the initial glucose level before
injection.
2.9. Statistical Analysis. Data are given as the mean ±
S.E.M. Statistical signiﬁcance of means for the studies was
determined by analysis of variance followed by Scheﬀe’s test.
P-values for signiﬁcance were set at 0.05.
3. Results and Discussion
3.1. Spectroscopic Studies. CyDs have been claimed to inter-
act with hydrophobic residues exposed on protein surfaces
and thereby to decrease the aggregation of proteins [22,
23]. We previously reported that SBE4-β-CyD inhibited the
aggregation of bovine insulin in neutral solution, possibly
due to the interaction of SBE4-β-CyD with aromatic side
chain of insulin such as B26-tyrosine, A19-tyrosine, B1-
phenylalanine, and B25-phenylalanine [17]. Also, our recent
study has shown that SBE4-β-CyD increased solubility of
insulin glargine, enhanced the dissolution rate from its
precipitate, and inhibited its aggregation in phosphate buﬀer
(pH 9.5, I = 0.2), with all possibly due to the formation of
complex with insulin glargine [19]. In the present study, to
reveal whether the selected anionic CyD derivatives, Sul-β-
CyD, and SBE7-β-CyD, interact with insulin glargine, the
eﬀects of both of the selected anionic β-CyDs (10mM)
on the ﬂuorescence and CD spectra of insulin glargine
were investigated (0.1mM) (Figure 2). To obtain the clear
solution of insulin glargine (0.1mM) in spectroscopic stud-
ies, insulin glargine with the selected anionic β-CyDs was
dissolved in phosphate buﬀer (pH 9.5, I = 0.2) at 25◦C.
The ﬂuorescence intensity of tyrosine of insulin glargine
at 306nm was remarkably quenched by the addition of
Sul-β-CyD (10mM) while SBE7-β-CyD (10mM) quenched
slightly (Figure 2(a)). As tyrosine is a hydrophobic amino
acid having a phenyl group in the molecule, these selected
anionic β-CyDs may interact with those aromatic amino
acid residues of insulin glargine. The apparent 1:1 stability
constants (Kc) of the insulin glargine/Sul-β-CyD complex
and insulin glargine/SBE7-β-CyD complex were determined
by the titration curves of the ﬂuorescence intensity against
the concentration of the selected anionic β-CyD with the
Scott’sequation[21].TheKc valuesofinsulinglargine/Sul-β-
CyD complex and insulin glargine/SBE7-β-CyD complex in
phosphate buﬀer (pH 9.5, I = 0.2) at 25◦C were calculated
to be 14 ± 3M −1 and 18 ± 4M −1,r e s p e c t i v e l y .T h eC D
spectrum of insulin glargine (0.1mM) showed negative
bands at 210nm and 220nm in phosphate buﬀer (pH 9.5,
I = 0.2) (Figure 2(b)). The two negative bands assigned to
α-helics (a characteristic feature of the monomer) and β-
sheets (a predominant feature of dimer) structures [24].
In the presence of Sul-β-CyD (10mM), the both negative
bands at 210nm and 220nm in the CD spectrum of insulin
glargine remarkably increased. These results indicate that
Sul-β-CyD decreased the content of monomer and dimer
of insulin glargine in phosphate buﬀer (pH 9.5, I = 0.2).
Meanwhile, the CD spectrum of insulin glargine in the
presence of SBE7-β-CyD was changed only very slightly,
compared to that of insulin glargine alone, suggesting that
SBE7-β-CyD did not induce a conformational change of
insulinglargineinphosphatebuﬀer(pH9.5,I =0.2).Togain
insight into the mechanism of the interaction mode of these4 Journal of Drug Delivery
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Figure 2: Eﬀects of Sul-β-CyD and SBE7-β-CyD (10mM) on ﬂuorescence spectrum (a), circular dichroism spectrum of insulin glargine
(0.1mM) in phosphate buﬀer (pH 9.5, I = 0.2) at 25◦C. The excitation wavelength in measurement of ﬂuorescence spectrum was 277nm.
anionic β-CyDs with insulin glargine, further investigation
should be required using NMR technique. Collectively, these
results strongly suggest that the interaction mode of Sul-
β-CyD and SBE7-β-CyD against insulin glargine is much
diﬀerent; namely, Sul-β-CyD, but not SBE7-β-CyD, induces
topological change of insulin glargine in phosphate buﬀer
(pH 9.5, I = 0.2), and this diﬀerence may contribute to
explaining the observed diﬀerences in in vivo behavior as
well.
3.2.SolubilityStudies. Thepreferredpresentationforadmin-
istration by subcutaneous injection is a clear aqueous
solution, and so this is the desired form for administration
of insulin and its analogues. However, insulin or insulin ana-
logues are poorly soluble in aqueous solution, in particular
at around their isoelectric point (pI), approximately pH 6.7,
closetothephysiologicalpH[25].Hence,theeﬀectsofSul-β-
CyD and SBE7-β-CyD on solubility of insulin glargine were
examined. As shown in Figure 3, the solubility of insulin
glargine in phosphate buﬀer at pH 9.5 was signiﬁcantly
increased by the addition of Sul-β-CyD or SBE7-β-CyD and
so appears to be due to an inclusion complexation and
electrostatic interaction between insulin glargine and the
selected anionic β-CyDs. These results suggest that Sul-β-
CyD and SBE7-β-CyD potentially enhance the solubility of
insulin glargine in phosphate buﬀer.
3.3. Ultraﬁltration Studies. The aggregation and self-
association of insulin and its analogue are elicited by many
kinds of factors such as the concentration of insulin, pH,
temperature,shaking,andsoon[5,6].Insulinglargineforms
dimer, tetramer, hexamer, and further soluble oligomers by
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Figure 3: Eﬀects of Sul-β-CyD and SBE7-β-CyD (10mM) on
solubility of insulin glargine in phosphate buﬀer (pH 9.5, I = 0.2)
at 25◦C. Each value represents the mean ± S.E.M. of 3 experiments.
∗P<0.05, compared to insulin glargine.
noncovalent interactions such as proceeding from self-
association [26, 27]. Therefore, we performed ultraﬁltration
studies to estimate the eﬀects of Sul-β-CyD and SBE7-β-CyD
on self-association of insulin glargine using the membrane
YM30 (MWCO = 30,000) in phosphate buﬀer (pH 9.5, I =
0.2). As shown in Figure 4, insulin glargine in the absence
of β-CyDs permeated the ultraﬁltration membrane by
approximately 50%. SBE7-β-CyD signiﬁcantly enhanced
the permeation of insulin glargine up to almost 70%. TheseJournal of Drug Delivery 5
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Figure 4: Eﬀects of Sul-β-CyD and SBE7-β-CyD (10mM) on per-
meation of insulin glargine (0.1mM) through ultraﬁltration mem-
brane having nominal molecular weight limit of 30,000 in phos-
phate buﬀer (pH 9.5, I = 0.2) at 25◦C. Each value represents the
mean ± S.E.M. of 17 and 5 experiments for insulin glargine and
with Sul-β-CyD or SBE7-β-CyD, respectively. ∗P<0.05, compared
to insulin glargine. #P<0.05, compared to Sul-β-CyD.
results suggest that interaction with SBE7-β-CyD results in
dissociation of such soluble oligomers of insulin glargine.
On the other hand, the presence of Sul-β-CyD slightly, but
signiﬁcantly decreased the permeation of insulin glargine
to approximately 45%, although not accompanied by
observable formation of insoluble aggregates of insulin
glargine under the prevailing experimental condition. Recall
from above, that Sul-β-CyD decreased the contents of
monomer and dimer of insulin glargine in phosphate buﬀer
(pH9.5,I = 0.2)(Figure 2(b)).Therefore,these results,taken
together, indicate that Sul-β-CyD enhanced the association
of soluble oligomer of insulin glargine from its monomer
and dimer.
3.4. Particle Size Determination. The apparent particle sizes
of insulin glargine were determined by the dynamic light
scattering method in the absence and presence of Sul-β-CyD
and SBE7-β-CyD (Table 1). Particle size of insulin glargine
aloneinphosphatebuﬀer(pH9.5,I =0.2)wasdeterminedas
744 ± 82nm. Particle sizes of insulin glargine in the presence
of Sul-β-CyD and SBE7-β-CyD increased signiﬁcantly to
1334 ± 164nm and 1575 ± 228nm, respectively. It is
estimated that the sulfate and sulfobutyl groups of Sul-β-
CyD and SBE7-β-CyD are both strongly hydrated in aqueous
solution. Therefore, these results suggest that Sul-β-CyD and
SBE7-β-CyD enhanced the particle size of insulin glargine in
phosphate buﬀer.
3.5. Dissolution Study of Insulin Glargine. Insulin glargine
is believed to precipitate at the physiological pH after
Table 1: Particle size of insulin glargine with or without Sul-β-CyD
and SBE7-β-CyD (10mM) in phosphate buﬀer (pH 9.5). The par-
ticle size was measured by a Zetasizer Nano. The concentrations of
insulin glargine and β-CyDs were 0.1mM and 10mM, respectively.
Each value represents the mean ± S.E.M. of 5–7 experiments.
System Diameter (nm)
Insulin glargine 744 ±82
With Sul-β-CyD 1334 ±164
∗
With SBE7-β-CyD 1575 ±228
∗
Uehata et al. [19]
subcutaneous injection of the solution due to pI (about
pH 6.7), which is followed by a sustained release of insulin
glargine over 24h at an injection site because of its extremely
low solubility in aqueous solution at pH of around pI [6].
In order to investigate the eﬀects of Sul-β-CyD and SBE7-
β-CyD on the sustained release of insulin glargine, the dis-
solution rate of insulin glargine from isoelectric precipitates
formed with or without β-CyDs was determined (Figure 5).
Insulin glargine (0.1mM) was dissolved in phosphate buﬀer
(pH 9.5) in the presence and absence of β-CyDs (10mM),
and then isoelectric precipitation of insulin glargine was
obtained after pH shift from 9.5 to 7.4. Then, the release
rate of insulin glargine was determined in phosphate buﬀer
(pH 7.4) in the absence of selected anionic β-CyDs. SBE7-
β-CyD signiﬁcantly increased the dissolution rate of insulin
glargine after 24h, compared to insulin glargine alone. This
enhancing eﬀect of SBE7-β-CyD on the dissolution rate is
consistent with its solubilizing eﬀect as shown in Figure 3.
On the other hand, Sul-β-CyD appeared to decrease the
dissolution rate of insulin glargine after 24h; however, no
statistical signiﬁcance was found. The inhibitory eﬀect of
Sul-β-CyD on the dissolution rate of insulin glargine from
its precipitate may be ascribed to the enhancement of the
association of insulin glargine molecules that is dominant
over the solubilizing eﬀect of Sul-β-CyD on insulin glargine.
To reiterate, SBE7-β-CyD, and not Sul-β-CyD, increases
dissolution of insulin glargine from its precipitate.
3.6. Stability of Insulin Glargine against Tryptic Cleavage.
Insulin and its analogues are digested by proteases such as
trypsin, which cleaves insulin at the carboxyl side of residues
B22-arginineandB29-lysine,ataninjectionsiteandsystemic
circulation [28]. Therefore, a resistance towards enzymatic
degradation is required for a formulation of insulin or its
analogues to demonstrate improvement in bioavailability.
Next, the eﬀects of Sul-β-CyD and SBE7-β-CyD on stability
of insulin glargine against trypsin digestion were investi-
gated. In this study, insulin glargine was digested by trypsin
at 2IU at pH 9.5 at 37◦Cw i t hd i ﬀerent degradation rates in
theabsenceandpresenceofβ-CyDs.AsshowninFigure 6(a),
the apparent degradation rate constant of insulin glargine
alone (k0) was 0.357 ± 0.004h−1. Meanwhile, the apparent
rate constants (kobs) in the presence of Sul-β-CyD and SBE7-
β-CyD decreased with the increase in the concentration of
these β-CyDs. The decline in the kobs value in the SBE7-β-
CyD system was more than that in the Sul-β-CyD system.6 Journal of Drug Delivery
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Figure 5:EﬀectsofSul-β-CyDandSBE7-β-CyD(10mM)ondisso-
lutionfromisoelectricprecipitationofinsulinglargineinphosphate
buﬀer (pH 9.5, I = 0.2) at 25◦C. The initial concentration of insulin
glargine was 0.1mM and then precipitated in phosphate buﬀer (pH
7.4). Each point represents the mean ± S.E.M. of 3 experiments.
∗P<0.05, compared to insulin glargine. #P<0.05, compared to
Sul-β-CyD.
T h er a t ec o n s t a n t s( kc) and stability constants (Kc)o ft h e
1:1 complex calculated with the regression lines shown in
the Figure 6(b) were 0.129 ± 0.009h−1 and 244 ± 24M−1
in the Sul-β-CyD system and 0.137 ± 0.014h−1 and 182 ±
22M−1 intheSBE7-β-CyDsystem,respectively.Theseresults
suggest that the inhibition of tryptic cleavage of insulin
glargine by Sul-β-CyD and SBE7-β-CyD may be ascribed to
the formation of the soluble oligomer and soluble complex
with insulin glargine (Figures 3 and 4), respectively, resulting
from decreasing the extent of the free insulin glargine that
could be easily digested by trypsin. Our previous studies
revealed that the kc and Kc values in the SBE4-β-CyD system
were 0.145 ± 0.012h−1 and 144 ± 18M−1,r e s p e c t i v e l y[ 19].
Therefore, it is evident that the inhibitory eﬀect of SBE7-β-
CyD on enzymatic degradation of insulin glargine is more
potent than that of SBE4-β-CyD.
Recently, it has been reported that the aspartic acid
residue existing in the catalytic pocket of trypsin is respon-
sible for attracting and stabilizing positively charged lysine
and/or arginine on the substrate peptide [29]. There-
fore, the insulin glargine/Sul-β-CyD interaction or insulin
glargine/SBE7-β-CyD complex is speculated to ameliorate
the interaction between the negatively charged aspartic acid
in the catalytic pocket of trypsin and positively charged
lysine and/or arginines mentioned earlier, since Sul-β-CyD
and SBE7-β-CyD have negative charge originating from the
sulfate and sulfonate groups, respectively. This hypothesis in
whichtheinsulinglargine/Sul-β-CyDinteractionandinsulin
glargine/SBE7-β-CyD complex ameliorate the interaction
between the aspartic acid and lysine and/or arginines is
supported by the ﬁnding that the aromatic amino acid
residues in insulin glargine which are capable of interacting
with β-CyDs (at B24-, B25-phenylalanines, B26-tyrosine,
and B28-proline) locate near the three digestive sites by
trypsin(B22-B23,B29-B30,andB31-B32)[17].Theseresults
suggest that Sul-β-CyD and SBE7-β-CyD act as stabilizers
of insulin glargine against enzymatic degradation by their
respective interactions with insulin glargine.
3.7. Subcutaneous Administration of Insulin Glargine/β-CyDs
Solutions to Rats. To conﬁrm whether Sul-β-CyD and SBE7-
β-CyD are useful excipients for insulin glargine in vivo,w e
evaluated the eﬀects of the β-CyDs on pharmacokinetics
and pharmacodynamics of insulin glargine after subcuta-
neous injection to rats. In our preliminary studies, we
found that neither Sul-β-CyD (100mM) nor SBE7-β-CyD
(100mM) changed the serum glucose level-time proﬁles
remarkably in comparison with that of insulin glargine
alone (2IU/kg) after subcutaneous injection to rats (data
not shown). Taking the positive results of SBE7-β-CyD in
ultraﬁltration (Figure 2) and dissolution (Figure 3) studies
by contrast to those of Sul-β-CyD into account, further in
vivoinvestigationwasperformedwithahigherconcentration
of SBE7-β-CyD. Figure 7(a) and Table 2 show the serum
insulin glargine level-time proﬁles and pharmacokinetics
parameters, respectively, after subcutaneous administration
of insulin glargine (2IU/kg) with or without SBE7-β-CyD
(200mM)inphosphatebuﬀer(pH9.5)torats.Wheninsulin
glargine alone was injected, the maximum level (Cmax)o f
insulin glargine and the time (Tmax) required to the reach
Cmax after injection were 150 μU/mL and 1.00h, respectively.
In the presence of SBE7-β-CyD (200mM), Cmax signiﬁcantly
decreased to 91.60 μU/mL although Tmax did not change
remarkably, compared to that of insulin glargine alone.
The area under the serum insulin glargine level-time curve
(AUC) in the SBE7-β-CyD system (200mM) up to 12h
(687.86 (μU/mL)·h) was signiﬁcantly increased, compared
to those of insulin glargine alone (582.99 (μU/mL)·h).
In addition, SBE7-β-CyD (200mM) extended the mean
residence time (MRT) of the serum insulin glargine level
signiﬁcantly, comparing with that of insulin glargine alone.
These results indicate that SBE7-β-CyD sustained the serum
insulin glargine level.
Figure 7(b) and Table 3 show the serum glucose level-
time proﬁles and pharmacodynamics parameters after sub-
cutaneous administration of insulin glargine (2IU/kg) with
or without SBE7-β-CyD (200mM) in the phosphate buﬀer
(pH 9.5) to rats. When insulin glargine alone was admin-
istered, the time to nadir blood glucose concentration
(Tnadir) was 1.6h after injection, and then the blood
glucose levels recovered within 6h to basal level. On the
other hand, insulin glargine administered with SBE7-β-CyD
signiﬁcantly retained the blood-glucose lowering eﬀect upJournal of Drug Delivery 7
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Figure 6: Eﬀects of Sul-β-CyD and SBE7-β-CyD (5 to 20mM) on tryptic cleavage (2IU) of insulin glargine (0.1mM) in phosphate buﬀer
(pH 9.5, I = 0.2) at 37◦C. Each point represents the mean ± S.E.M. of 3 experiments.
Table 2: In vivo pharmacokinetics parameters of insulin glargine with or without SBE7-β-CyD (200mM). (1) Time required to reach the
maximum serum insulin glargine level. (2) Maximum serum insulin glargine level. (3) Area under the serum insulin glargine level-time
curve up to 12h after-administration. (4) Mean residence time in plasma. Each value represents the mean ± S.E.M. of 4–6 experiments.
∗P<0.05, compared to insulin glargine.
System T
(1)
max (h) C
(2)
max (μU/mL) AUC(3)
((mU/mL)h) MRT(4) (h)
Insulin glargine 1.00 ±0.00 150.00 ±17.90 582.99 ±30.27 1.83 ±0.08
Insulin
glargine/SBE7-β-CyD 1.40 ±0.24 91.60 ±3.04
∗ 687.86 ±20.57
∗ 2.12 ±0.04
∗
to 6h after administration. Tnadir was signiﬁcantly increased
in the insulin glargine/SBE7-β-CyD system. Further, the
insulin glargine/SBE7-β-CyD system showed the tendency
to augment the area under serum glucose level-time curve
(AUCG). The retained blood-glucose lowering eﬀects and
enhancement of Tnadir by the addition of SBE7-β-CyD may
becontributedto(1)theinhibitoryeﬀectsofSBE7-β-CyDon
the enzymatic degradation of insulin glargine (Figure 6)a n d
(2) the enhancement of solubility and the dissolution rate of
insulin glargine by SBE7-β-CyD (Figures 3–5). However, the
enhancement of bioavailability and persistence of the blood-
glucose lowering eﬀect of insulin glargine after subcutaneous
injection to rats by SBE7-β-CyD was not superior to that
of SBE4-β-CyD. The reason for this may be due to the
diﬀerence in adsorption of insulin glargine onto the subcu-
taneous tissue at injection site between the SBE7-β-CyD and
SBE4-β-CyD systems [19]. To gain insight into the detailed
mechanism, further study on the adsorption of insulin
glargine in the presence of SBE-β-CyDs onto subcutaneous
tissue at injection site is underway. These results suggest
that SBE7-β-CyD increased the bioavailability and persis-
tence of the blood-glucose lowering eﬀect of insulin glargine
after subcutaneous administration of an insulin glargine
solution to rats.
4. Conclusions
In the present study, we revealed that Sul-β-CyD and SBE7-
β-CyD increased solubility of insulin glargine. Furthermore,
SBE7-β-CyD suppressed the formation of oligomer and
enhanced the dissolution rate of insulin glargine from its
precipitate, compared to that of Sul-β-CyD. In addition,
we demonstrated that SBE7-β-CyD increased the bioavail-
ability and persistence of the blood-glucose lowering eﬀect
of insulin glargine after subcutaneous administration of
an insulin glargine solution to rats, probably due to the
inhibitory eﬀects of SBE7-β-CyD on the enzymatic degra-
dation at the injection site, resulting from the interaction8 Journal of Drug Delivery
Table 3: In vivo pharmacodynamics parameters of insulin glargine with or without SBE7-β-CyD (200mM). (1) Time to nadir blood glucose
concentration. (2) Nadir blood glucose concentration. (3) The cumulative percentage of change in serum glucose levels up to 12h after-
administration. (4) Mean residence time in plasma. Each value represents the mean ± S.E.M. of 5-6 experiments. ∗P<0.05, compared to
insulin glargine.
System T
(1)
nadir (h) C
(2)
nadir (%) AUC
(3)
G (% ·h) MRT
(4)
G (h)
Insulin glargine 1.60 ±0.16 33.14 ±1.10 544.66 ±31.73 2.28 ±0.03
Insulin glargine/
SBE7-β-CyD 3.50 ±0.05
∗ 32.05 ±4.73 612.36 ±40.84 2.29 ±0.01
S
e
r
u
m
i
n
s
u
l
i
n
g
l
a
r
g
i
n
e
l
e
v
e
l
(
μ
U
/
m
L
)
048 1 2
0
30
60
90
120
150
180
Time (h)
(200mM) With SBE7-β-CyD
Insulin glargine
∗ ∗
∗
∗
(a)
0
20
40
60
80
100
S
e
r
u
m
g
l
u
c
o
s
e
l
e
v
e
l
(
%
)
048 1 2
Time (h)
(200mM) With SBE7-β-CyD
Insulin glargine
∗
∗
(b)
Figure 7:EﬀectsofSBE7-β-CyD(200mM)onseruminsulinglargine(a)andglucose(b)levelsaftersubcutaneous administrationofinsulin
glargine (2IU/kg) to rats. Each point represents the mean ± S.E.M. of 4–6 experiments. ∗P<0.05, compared to insulin glargine.
with insulin glargine molecules. These ﬁndings indicate that
SBE7-β-CyD can be a useful excipient for a peakless proﬁle
of insulin glargine.
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